NKTR-255 in combination with durvalumab following chemoradiation was well-tolerated in patients with non–small cell lung ...

The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.

Therapeutics and collaborators at The University of Texas MD Anderson Cancer Center presented late-breaking results from a Phase ...

In a move aimed at providing relief to cancer patients, the National Pharmaceutical Pricing Authority (NPPA) has directed ...

Akeso begins patient enrollment in phase 3 trial of ivonescimab combination as first-line therapy for biliary tract tumours, compared to durvalumab: China Monday, November 4, 2024 ...

The top stories in non-small cell lung cancer (NSCLC) for 2024 included practice-changing results in EGFR-mutant disease, an ...

Govt asks manufacturers to cut price of 3 anti-cancer drugs The Indian government has instructed companies to lower the prices of anti-cancer drugs Trastuzumab, Osimertinib, and Durvalumab following ...

Osimertinib and Durvalumab – in line with the government’s commitment to ensure the availability of drugs at affordable ...

The maximum retail prices (MRP) of three main drugs used in the treatment of cancer, viz, Trastuzumab, Osimertinib and ...

New Delhi- The government has asked the companies to reduce prices of three anti-cancer drugs to pass on the benefit of ...

The National Pharmaceutical Pricing Authority (NPPA) on Tuesday issued a memorandum directing drug manufacturers to reduce ...

While presenting the Union Budget for 2024-25 in the Lok Sabha, Finance Minister Nirmala Sitharaman proposed to cut customs duties on Trastuzumab, Osimertinib and Durvalumab from 10 per cent to nil.